Duality Advisers LP Purchases Shares of 45,975 R1 RCM Inc. (NASDAQ:RCM)

Duality Advisers LP purchased a new stake in R1 RCM Inc. (NASDAQ:RCM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,975 shares of the healthcare provider’s stock, valued at approximately $486,000.

Other institutional investors also recently modified their holdings of the company. Headlands Technologies LLC bought a new position in shares of R1 RCM in the third quarter valued at $36,000. ANTIPODES PARTNERS Ltd grew its position in R1 RCM by 429.5% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock worth $59,000 after purchasing an additional 4,561 shares in the last quarter. Salem Investment Counselors Inc. purchased a new position in R1 RCM during the 4th quarter worth approximately $61,000. Van ECK Associates Corp grew its position in R1 RCM by 28.5% during the 3rd quarter. Van ECK Associates Corp now owns 5,097 shares of the healthcare provider’s stock worth $77,000 after purchasing an additional 1,130 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in R1 RCM during the 3rd quarter worth approximately $189,000. Institutional investors own 61.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on RCM shares. Citigroup upgraded shares of R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Wednesday, March 20th. Canaccord Genuity Group lowered their price objective on shares of R1 RCM from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, March 20th. Morgan Stanley reiterated an “overweight” rating and set a $17.00 price objective on shares of R1 RCM in a research report on Tuesday, March 26th. KeyCorp restated a “sector weight” rating on shares of R1 RCM in a report on Wednesday, April 10th. Finally, Truist Financial restated a “hold” rating and set a $16.00 price target on shares of R1 RCM in a report on Monday, April 1st. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.87.

R1 RCM Price Performance

Shares of NASDAQ:RCM opened at $11.82 on Friday. R1 RCM Inc. has a 1 year low of $8.87 and a 1 year high of $18.70. The firm has a fifty day moving average price of $12.81 and a 200 day moving average price of $11.47. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.57.

Insider Buying and Selling

In related news, President John M. Sparby sold 10,046 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $14.33, for a total value of $143,959.18. Following the completion of the sale, the president now directly owns 265,986 shares in the company, valued at $3,811,579.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 36.80% of the stock is currently owned by corporate insiders.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.